Business
Daiichi Sankyo Concludes pCPA Letter of Intent for Vanflyta® in Newly Diagnosed FLT3-ITD Positive AML
Vanflyta® (quizartinib) is now publicly reimbursed in Canada in Quebec, enabling access for adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) across induction, consolidation and maintenance phases of treatment (with or without transplant).1 This follows the execution of a Letter of Intent with the pCPA and after Vanflyta received its Notice of Compliance from Health Canada in June 2025.
About this update from Daiichi Sankyo Company, Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Completion of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations enables public reimbursement of Vanflyta across Canada, with Quebec reimbursing Vanflyta in May 2026","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Reimbursement includes use across induction, consolidation and maintenance phases of treatment","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":275,"olType":false},{"type":"text","content":"TORONTO, May 28, 2026 /CNW/ - Vanflyta® (quizartinib) is now publicly reimbursed in Canada in Quebec, enabling access for adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) across induction, consolidation and maintenance phases of treatment (with or without transplant).1 This follows the execution of a Letter of Intent with the pCPA and after Vanflyta received its Notice of Compliance from Health Canada in June 2025.","length":467,"tagName":"p"},{"type":"image","alt":"Daichii Sankyo Logo (CNW Group/Daiichi Sankyo)","displaySize":"","headline":null,"caption":"Daichii Sankyo Logo (CNW Group/Daiichi Sankyo)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":395,"url":"https://media.zenfs.com/en/cnwgroup.com/9add49c6e1e18ff1d544c12d40808578"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAb9k7cL95gOLYuJYyhs_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTY5Ng--/https://media.zenfs.com/en/cnwgroup.com/9add49c6e1e18ff1d544c12d40808578","width":400,"height":395},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/LVR5PCmcvFo2n2exCa7ong--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTYzMg--/https://media.zenfs.com/en/cnwgroup.com/9add49c6e1e18ff1d544c12d40808578","width":400,"height":395}},"href":"https://mma.prnewswire.com/media/2990043/Daiichi_Sankyo_Daiichi_Sankyo_Concludes_pCPA_Letter_of_Intent_fo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Vanflyta is a FLT3 inhibitor being developed and commercialized by Daiichi Sankyo (TSE: 4568) for the treatment of patients with newly-diagnosed FLT3-ITD positive AML, with approximately 25% of all new AML cases being FLT3-ITD positive.1,2,3 A validated test is required to confirm the FLT3-ITD status of AML.1","length":310,"tagName":"p"},{"type":"text","content":"The approval of Vanflyta by Health Canada was based on ...